Konica Minolta, Inc. (KNCAY) Research

Konica Minolta, Inc. is a venerable Japanese corporation, founded in Tokyo in 1873, with a significant global footprint. The company's diverse operations span key areas including digital workplace solutions, professional printing, healthcare technology, and various industrial applications, serving markets across Japan, the United States, Europe, China, other Asian nations, and beyond. Its core business involves the creation, production, and distribution of multi-functional peripherals, advanced digital printing systems, and their essential consumables. Konica Minolta also delivers comprehensive IT and printing solutions, alongside tailored services to optimize these environments. In the healthcare sector, the firm provides sophisticated diagnostic imaging systems, encompassing digital X-ray and ultrasound technologies, among others. Furthermore, it offers extensive digitalization, networking, and service solutions for medical facilities, complemented by genetic testing, drug discovery support, and primary care services. Beyond these, Konica Minolta's expansive portfolio extends to precision measuring instruments, cutting-edge functional film displays, organic light-emitting diode (OLED) lighting products, industrial inkjet printheads, specialized lenses for industrial and professional use, and innovative imaging IoT and visual solutions.

Market snapshot

Symbol
KNCAY
Price
$7.22
Day change
0.00%
Market cap
$275.2B
P/E ratio
9.09x
52-week range
5.6-9.14
Sector
Industrials
Industry
Business Equipment & Supplies
Next earnings
in 1 month

Peer companies

  • AF Gruppen ASA (AGRUF)
  • Cadeler A/S (CADLF)
  • GEK TERNA Holdings, Real Estate, Construction S.A. (GKTRF)
  • Landis+Gyr Group AG (LGYRF)
  • Norwegian Air Shuttle ASA (NWARF)
  • Okamura Corporation (OKAMF)
  • Penta-Ocean Construction Co., Ltd. (PNOCF)
  • Shanghai Industrial Holdings Limited (SGHIY)

Open Konica Minolta, Inc. (KNCAY) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.